Javascript must be enabled to continue!
Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population
View through CrossRef
Objectives The objective of this study is to investigate differences in the diagnosis and management of systemic lupus erythematosus (SLE) by primary care and specialist physicians in a population-based registry. Methods This study includes individuals from the 2009 Indian Health Service lupus registry population with a diagnosis of SLE documented by either a primary care provider or specialist. SLE classification criteria, laboratory testing, and medication use at any time during the course of disease were determined by medical record abstraction. Results Of the 320 individuals with a diagnosis of SLE, 249 had the diagnosis documented by a specialist, with 71 documented by primary care. Individuals with a specialist diagnosis of SLE were more likely to have medical record documentation of meeting criteria for SLE by all criteria sets (American College of Rheumatology, 79% vs 22%; Boston Weighted, 82% vs 32%; and Systemic Lupus International Collaborating Clinics, 83% vs 35%; p < 0.001 for all comparisons). In addition, specialist diagnosis was associated with documentation of ever having been tested for anti-double-stranded DNA antibody and complement 3 and complement 4 ( p < 0.001). Documentation of ever receiving hydroxychloroquine was also more common with specialist diagnosis (86% vs 64%, p < 0.001). Conclusions Within the population studied, specialist diagnosis of SLE was associated with a higher likelihood of having SLE classification criteria documented, being tested for biomarkers of disease, and ever receiving treatment with hydroxychloroquine. These data support efforts both to increase specialist access for patients with suspected SLE and to provide lupus education to primary care providers.
SAGE Publications
Title: Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population
Description:
Objectives The objective of this study is to investigate differences in the diagnosis and management of systemic lupus erythematosus (SLE) by primary care and specialist physicians in a population-based registry.
Methods This study includes individuals from the 2009 Indian Health Service lupus registry population with a diagnosis of SLE documented by either a primary care provider or specialist.
SLE classification criteria, laboratory testing, and medication use at any time during the course of disease were determined by medical record abstraction.
Results Of the 320 individuals with a diagnosis of SLE, 249 had the diagnosis documented by a specialist, with 71 documented by primary care.
Individuals with a specialist diagnosis of SLE were more likely to have medical record documentation of meeting criteria for SLE by all criteria sets (American College of Rheumatology, 79% vs 22%; Boston Weighted, 82% vs 32%; and Systemic Lupus International Collaborating Clinics, 83% vs 35%; p < 0.
001 for all comparisons).
In addition, specialist diagnosis was associated with documentation of ever having been tested for anti-double-stranded DNA antibody and complement 3 and complement 4 ( p < 0.
001).
Documentation of ever receiving hydroxychloroquine was also more common with specialist diagnosis (86% vs 64%, p < 0.
001).
Conclusions Within the population studied, specialist diagnosis of SLE was associated with a higher likelihood of having SLE classification criteria documented, being tested for biomarkers of disease, and ever receiving treatment with hydroxychloroquine.
These data support efforts both to increase specialist access for patients with suspected SLE and to provide lupus education to primary care providers.
Related Results
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus erythematosus) and non-s...
Crucial Role of Foxp3 Gene Expression and Mutation in Systemic Lupus Erythematosus, Inferred from Computational and Experimental Approaches
Crucial Role of Foxp3 Gene Expression and Mutation in Systemic Lupus Erythematosus, Inferred from Computational and Experimental Approaches
The impaired suppressive function of regulatory T cells is well-understood in systemic lupus erythematosus. This is likely due to changes in Foxp3 expression that are crucial for r...
BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS
BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS
Systemic Lupus Erythematosus is an autoimmune multisystem pathology, characterized by being more prevalent in women, especially African women. One of the most frequent pathologies ...
Impacts of man-made structures on marine biodiversity and species status - native & non-native species
Impacts of man-made structures on marine biodiversity and species status - native & non-native species
<p>Coastal environments are exposed to anthropogenic activities such as frequent marine traffic and restructuring, i.e., addition, removal or replacing with man-made structur...
Checklist of the avian diversity of Alaska
Checklist of the avian diversity of Alaska
More than just a state, Alaska constitutes the entire northwestern extent of North America. Alaska is a vast area (586,412 mi2/1,518,800 km2 of land), spanning nearly 60 degrees of...
SYSTEMIC LUPUS ERYTHEMATOSUS: UPDATE ΟN THE DIAGNOSIS, PREVALENCE, CLINICAL MANAGEMENT, INFLAMMATORY MARKERS, NEW HORIZONS IN THE PATHOGENESIS, MANIFESTATIONS AND PROGRESS IN TREATMENT
SYSTEMIC LUPUS ERYTHEMATOSUS: UPDATE ΟN THE DIAGNOSIS, PREVALENCE, CLINICAL MANAGEMENT, INFLAMMATORY MARKERS, NEW HORIZONS IN THE PATHOGENESIS, MANIFESTATIONS AND PROGRESS IN TREATMENT
Introduction: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement, generating chronic inflammation and damage of more than one organ. I...
MO215DEPRESSIVE DISORDER IN LUPIC PATIENTS WITH LUPUS NEPHRITIS: DATA FROM A POPULATION OF 67 PATIENTS WITH BIOPSY PROVEN LUPUS NEPHRITIS
MO215DEPRESSIVE DISORDER IN LUPIC PATIENTS WITH LUPUS NEPHRITIS: DATA FROM A POPULATION OF 67 PATIENTS WITH BIOPSY PROVEN LUPUS NEPHRITIS
Abstract
Background and Aims
Systemic lupus erythematosus is a multi-organ, multi-systemic autoimmune disease with significant b...
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Three in One: Systemic Lupus Erythematosus, HELLP Syndrome, and Antiphospholipid Syndrome: A Case Report and Literature Review
Abstract
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease commonly affecting women of reproductive age. Its overlap with HELLP syndrome (Hemolysi...

